These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29249594)

  • 1. Anatomic versus Metabolic Tumor Response Assessment after Radioembolization Treatment.
    Jongen JMJ; Rosenbaum CENM; Braat MNGJA; van den Bosch MAAJ; Sze DY; Kranenburg O; Borel Rinkes IHM; Lam MGEH; van den Hoven AF
    J Vasc Interv Radiol; 2018 Feb; 29(2):244-253.e2. PubMed ID: 29249594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.
    Shady W; Kishore S; Gavane S; Do RK; Osborne JR; Ulaner GA; Gonen M; Ziv E; Boas FE; Sofocleous CT
    Eur J Radiol; 2016 Jun; 85(6):1224-31. PubMed ID: 27161074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into the Dose-Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases.
    van den Hoven AF; Rosenbaum CE; Elias SG; de Jong HW; Koopman M; Verkooijen HM; Alavi A; van den Bosch MA; Lam MG
    J Nucl Med; 2016 Jul; 57(7):1014-9. PubMed ID: 26912436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres.
    Shady W; Sotirchos VS; Do RK; Pandit-Taskar N; Carrasquillo JA; Gonen M; Sofocleous CT
    AJR Am J Roentgenol; 2016 Sep; 207(3):661-70. PubMed ID: 27384594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
    Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
    J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.
    Wong CY; Salem R; Raman S; Gates VL; Dworkin HJ
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):815-20. PubMed ID: 12029557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decrease in total lesion glycolysis and survival after yttrium-90-radioembolization in poorly differentiated hepatocellular carcinoma with portal vein tumour thrombosis.
    Filippi L; Di Costanzo GG; D'Agostini A; Tortora R; Pelle G; Cianni R; Schillaci O; Bagni O
    Nucl Med Commun; 2018 Sep; 39(9):845-852. PubMed ID: 29901488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
    Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early metabolic response assessment of breast cancer liver metastases: 4-week posttreatment FDG PET predicts survival after 90Y microsphere radioembolization.
    Sabet A; Ries M; Al-Khalaf Y; Meyer C; Rudlowski C; Simon B; Khreish F; Ezziddin S
    Nuklearmedizin; 2019 Jun; 58(3):242-248. PubMed ID: 31167272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal liver metastasis after 90Y radioembolization therapy: pilot study of change in MDCT attenuation as a surrogate marker for future FDG PET response.
    Tochetto SM; Töre HG; Chalian H; Yaghmai V
    AJR Am J Roentgenol; 2012 May; 198(5):1093-9. PubMed ID: 22528898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma.
    Sager S; Akgün E; Uslu-Beşli L; Asa S; Akovali B; Sahin O; Yeyin N; Demir M; Abuqbeitah M; Gülsen F; Sayman H; Sönmezoglu K
    Nucl Med Commun; 2019 May; 40(5):461-468. PubMed ID: 30896544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
    Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
    J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization.
    Hwang SH; Hong HS; Kim D; Kim GM; Lee HW; Lee M; Kim DY; Park MA; Yun M
    Clin Nucl Med; 2022 Jun; 47(6):e437-e443. PubMed ID: 35384891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-Energy Computed Tomography-Based Iodine Quantitation for Response Evaluation of Lung Cancers to Chemoradiotherapy/Radiotherapy: A Comparison With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-Based Positron Emission Tomography/Computed Tomography Response Evaluation Criterion in Solid Tumors.
    Ren Y; Jiao Y; Ge W; Zhang L; Hua Y; Li C; Zhai W; Tang X; He W; Fang M; Zheng X
    J Comput Assist Tomogr; 2018; 42(4):614-622. PubMed ID: 29613988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.
    Zerizer I; Al-Nahhas A; Towey D; Tait P; Ariff B; Wasan H; Hatice G; Habib N; Barwick T
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1391-9. PubMed ID: 22644713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of post-Yttrium 90 radioembolization therapy 18F-fluorodeoxyglucose positron emission tomography in patients with liver tumors.
    Obrzut S; McCammack K; Badran KW; Balistreri A; Ou E; Nguyen BJ; Hoh CK; Rose SC
    Clin Imaging; 2017; 42():43-49. PubMed ID: 27875761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
    Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer.
    Sabet A; Meyer C; Aouf A; Sabet A; Ghamari S; Pieper CC; Mayer K; Biersack HJ; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):370-6. PubMed ID: 25351506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic accuracy of diffusion-weighted magnetic resonance imaging versus positron emission tomography/computed tomography for early response assessment of liver metastases to Y90-radioembolization.
    Barabasch A; Kraemer NA; Ciritsis A; Hansen NL; Lierfeld M; Heinzel A; Trautwein C; Neumann U; Kuhl CK
    Invest Radiol; 2015 Jun; 50(6):409-15. PubMed ID: 25763526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.